Chengdu Beite Denuo Pharmaceutical Co., Ltd.

This product is a cell cycle-specific anti-tumor drug that acts on DNA topoisomerase II to form a stable reversible complex of drug-enzyme-DNA, which hinders DNA repair. Experiments have found that this complex can be reversed with the elimination of the drug, allowing the damaged DNA to be repaired and reducing cytotoxicity. Therefore, extending the drug administration time may increase the anti-tumor activity.

Bioester alkaloids with anticancer effects extracted from Cephalotaxus plants can inhibit the synthesis of eukaryotic cell proteins, disaggregate polyribosomes, and interfere with the function of protein nucleosome sugars. It also has an inhibitory effect on the synthesis of intracellular DNA. In vitro experiments show that it has the strongest killing effect on G1 and G2 phase cells, but has a smaller effect on S phase cells. There is no cross-resistance with cytarabine, mercaptopurine, etc.

This product is a new type of anti-microtubule drug. It promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability, and inhibits cell mitosis. In vitro experiments have shown that paclitaxel has a significant radiosensitization effect, which may be to stop cells in the G2 and M phases that are sensitive to radiotherapy. Paclitaxel is a mitotic inhibitor or spindle poison. It has a different mechanism of action from the commonly used chemotherapy drugs. It induces and promotes the assembly of microtubules. Paclitaxel has the effect of polymerizing and stabilizing microtubules, causing rapidly dividing tumor cells to be firmly fixed in the mitotic stage, blocking the replication of cancer cells and causing them to die.